Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 109 UK neurodegenerative disease companies below.
Precision calcium channel medicines for epilepsy and Parkinson's disease
Lario Therapeutics is developing first-in-class precision medicines as disease-modifying treatments for severe neurological disorders, including genetically defined epileptic encephalopathies and Parkinson's disease. The company's pipeline centres on neuronal calcium channel inhibitors, beginning with genetically…
Precision-programmed human iPSC-derived cells for biomedical research
bit.bio is a Cambridge-based synthetic biology company that programmes human induced pluripotent stem cells into defined, mature cell types for use in pharmaceutical and academic research. Its precision cell programming technology produces consistent, characterised human cells at industrial scale, supporting drug…
Global biopharma focused on neurology and rare disease therapeutics
Biogen is a global biopharma company and one of the world's first biotechnology firms. The UK and Ireland headquarters in Maidenhead employs approximately 250 people across clinical operations, regulatory affairs, drug safety, and medical affairs. The company develops and commercialises therapies for neurological,…
Antibody therapeutics targeting glycosphingolipid inflammation
Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma. The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen…
AAV gene therapy platform and clinical pipeline for genetic disease
AskBio UK Ltd is the European headquarters of AskBio Inc., a fully integrated AAV gene therapy company and Bayer AG subsidiary. Operating from Roslin Innovation Centre, the Edinburgh site develops the company's synthetic promoter technology, data-driven gene expression control sequences that complement AskBio's Pro10…
Antibody therapies targeting severe autoimmune diseases
argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases. The company markets VYVGART (efgartigimod), the first approved FcRn blocker in the UK, indicated for generalised myasthenia gravis and chronic inflammatory…
RNAi brain shuttle platform for neurodegenerative disease drug delivery
Aerska is a biotechnology company developing RNA interference medicines to treat, delay and prevent diseases of the brain. The company's antibody oligonucleotide conjugate platform acts as a brain shuttle, enabling RNAi therapeutics to cross the blood brain barrier and reach the central nervous system through systemic…
Precision medicine platform for patient recruitment and genetic testing
Sano Genetics is a London-based software company providing an end-to-end platform for patient recruitment, at-home genetic testing, and long-term participant engagement in precision medicine clinical trials and population genomics programmes. The platform integrates DNA testing logistics, medical history retrieval,…
Targeting mitochondrial dysfunction in neurodegeneration
NRG Therapeutics is a clinical-stage neuroscience company developing small molecule inhibitors of the mitochondrial permeability transition pore as disease-modifying treatments for neurodegenerative disorders. Its lead candidate, NRG5051, entered Phase 1 clinical trials in January 2026 for ALS and Parkinson's disease.…
Preclinical neuroscience CRO for translational drug development research
Transpharmation is a preclinical neuroscience contract research organisation providing translational pharmacology services to pharmaceutical and biotechnology companies. The company's therapeutic expertise spans EEG, cognition, epilepsy, pain, neurodegeneration and mood disorders including treatment-resistant…
Causal cellular data and AI models for drug discovery
CellCodex is a biotechnology company that generates causal data from human cells to train predictive models for drug discovery. It programmes stem cells into pure, aged, disease-relevant cell types, perturbs them at genome scale with CRISPR and compounds, and reads the outcome in single cells. The company applies the…
Anti-inflammatory drugs for neurodegenerative disease
Sitala Bio is a Cambridge-based biotech developing small molecule drugs that target chronic neuroinflammation in conditions such as Parkinson's and Alzheimer's disease. The company's approach focuses on blocking microglial dysfunction to restore toxin clearance in the brain. Founded by NLRP3 inflammasome expert Matt…
Specialist CNS and psychiatric clinical trial design and delivery organisation
Clerkenwell Health is a London-based specialist contract research organisation providing clinical trial design, regulatory submission, and trial delivery services for CNS, psychiatric, and psychedelic-assisted therapy research. The company operates a purpose-built clinical site network, including an NHS-embedded…
Intranasal anti-CD3 immunotherapy for neuroinflammatory diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration. The 48-patient…
Macrophage-targeted therapeutics for oncology, neurological and fibrotic diseases
Macomics is a University of Edinburgh spin-out developing macrophage-targeted medicines across oncology, neurodegenerative, inflammatory and fibrotic diseases. Its ENIGMAC drug discovery platform combines human macrophage and microglia models derived from induced pluripotent stem cells, gene editing and…
AI-powered EEG platform for CNS clinical trials
Cumulus Neuroscience is a digital health software company providing an integrated brain monitoring and analytics platform for neuroscience clinical trials. Its platform combines a medical-grade EEG headset with machine learning analytics to generate objective, at-home physiological and cognitive biomarker data.…
Small molecule regulators of mitochondrial transfer for age related disease
Nascent Therapeutics is a biotechnology company developing small molecule therapies that regulate mitochondrial transfer between cells. The company's discovery platform identifies compounds that promote the uptake of healthy mitochondria into damaged cells, or block cancer cells from taking mitochondria from…
AI epigenomics platform for neurodegenerative disease detection
Prima Mente is a biotechnology company developing large-scale biological foundation models to understand and detect neurodegenerative disease. The company generates proprietary multi-omic data including whole-epigenome sequencing, and trains transformer-based models on DNA methylation patterns in cell-free DNA to…
DNA nanoprobes for intracellular biomarker profiling in neurodegeneration
Esya Labs is a precision biomarker company using patented DNA nanoprobes to measure ion signatures within intracellular organelles including endosomes and lysosomes. The technology enables ratiometric quantification of subcellular chemical states in living cells, with applications in early detection of…
siRNA gene therapies targeting root causes of ALS and frontotemporal dementia
Crucible Therapeutics Limited is a preclinical-stage biotechnology company developing siRNA-based gene therapies for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia caused by the C9orf72 gene mutation. Its therapeutic approach depletes the SRSF1 protein to suppress production of toxic dipeptide repeat…